Cambridge Drug Discovery Ltd.
This article was originally published in Start Up
Cambridge Drug Discovery was formed in 1997 by four Pfizer scientist who wanted to exploit expertise in assay development, high-throughput screening and informatics, to accelerate the drug discovery process. One of the company's discovery platforms is used to discover small-molecule modulators of G-Protein Coupled Receptors.
You may also be interested in...
Low influenza activity in the face of COVID-19 mitigation measures has made it more difficult to predict which strains may become predominant, but US FDA advisory committee unanimously endorses WHO recommendations for influenza A and B strains to be included in US trivalent and quadrivalent vaccines.
Agency cites “unexpected and large drop in collections” in slashing user-fee-setting contract.
Immuno-Oncology’s ‘Infancy’? ‘Adolescence?’ Wherever You Peg Development, Adverse Event Reporting Needs To Mature
A common toxicity of advanced IO therapies, cytokine release syndrome needs to be better characterized as part of the groundwork for future development of the field, according to Friends of Cancer Research.